Laura A. Brege
Independent DirectorMs. Laura A. Brege is Director of Numab Therapeutics AG from August 2024. Ms. Brege has been a Director at Pacira Pharmaceuticals Inc. since June 2011 and is its Chair of the Board from January 2025. She had been Independent Director at T-Knife GmbH since November 2021 until August 2026. She serves as an Independent Director of Mirum Pharmaceuticals, Inc. since July 2019. From September 2015 to June 2018, she was Managing Director of Cervantes Life Science Partners, LLC from September 2015 to June 2018. She serves as Independent Director at Edgewise Therapeutics, Inc. since December 2020. She has executive management experience in the pharmaceutical, biotechnology and venture capital industries. She served as the Chief Executive Officer and President of Nodality, Inc., from September 24, 2012 to July 2015. She has biotechnology and pharmaceutical industry experience with both privately-held and publicly-traded companies. Prior to joining Nodality in 2012, she served as an Executive Vice President of Corporate Affairs at Onyx Pharmaceuticals, Inc from January 2011 to January 2012 and served as its Executive Vice President from June 12, 2006 to January 2011. She served as a Consultant of Onyx Pharmaceuticals, Inc. from November 2011 to May 15, 2012. She served as the Chief Operating Officer of Onyx Pharmaceuticals October 2007 to January 2011. She served as the Chief Business Officer of Onyx Pharmaceuticals, Inc. from June 12, 2006 to October 2007. At Onyx, she led multiple functions, including commercialization, strategic planning, corporate development and medical, scientific and government affairs. She served as the Chief Financial Officer at Onyx. She served as the Chief Executive Officer at XDx, Inc. until October 2012. She served as a General Partner at Red Rock Ventures and Red Rock Ventures II, L.P. She served as the Treasurer of Red Rock Ventures. She served as a General Partner at Red Rock Capital Management Inc from 1999 to 2006. She served as the Senior Vice President at COR Therapeutics Inc and also served as its Chief Financial Officer from 1991 to 1999. She served as a Member of the Management Team that negotiated multiple corporate partnerships, including a worldwide co-promotion agreement for COR's lead product, as well as corporate partnerships for programs and products with J&J, Eli Lilly and Solvay. She served as a Vice President and Chief Financial Officer at Flextronics International Ltd. She served as a Vice President and Treasurer of The Cooper Companies Inc. She served as a Director of Aratana Therapeutics, Inc. since February 5, 2014 until March 14, 2019. Ms. Brege is an experienced healthcare executive with extensive public company experience. She serves as a Director of BayBio. She had been an Independent Director of Portola Pharmaceuticals, Inc. from February 2015 to July 2020. She serves as a Director of University Of Ohio, USA. Ms. Brege serves as a Senior Advisor to BridgeBio Pharma, Inc. since April 2018. She served as a Director of Bay Area Bioscience Association, Ohio University Endowment, The (The Ohio University Foundation) and Ohio University, Endowment Arm. She has been an Independent Director of ACADIA Pharmaceuticals, Inc. since May 5, 2008. She served as a Director of Zvents, Inc. since November 2006. She was an Independent Director of Pacira BioSciences, Inc since June 2011 until November 17, 2026 and was its Independent Chair of the Board since January 2025 until November 17, 2026. She served as a Director of Nodality, Inc since September 2012 until July 2015. She served as a Director of SoftCoin, Inc. She served as a Director of Avexus, Inc., since January 2004. She served as a Director of Angiotech Pharmaceuticals, Inc. from August 02, 2007 to 2011. She served as a Director of CareDx, Inc until October 2012. She served as Director at Dynavax Technologies Corporation since February 6, 2015 until February 13, 2020. She served as a Director of LiveCapital, Inc. She served as a Director of Delcath Systems, Inc. from July 5, 2012 to December 11, 2014. She had been an Independent Director at HLS Therapeutics Inc., since March 21, 2019 until August 07, 2024 and served on its Board. She is a Member of Foundation Board of Ohio University. She holds an M.B.A. from University of Chicago and a B.B.A. in Government and a B.S. in Economics and Political Science from Honors Tutorial College, Ohio University, where she graduated summa cum laude.
Positions
- Company NameAcadia Pharmaceuticals Inc.Stock CodeACADPositionIndependent DirectorColleagues
- CECatherine E. Owen AdamsCEO & Director
- SRStephen Richard BiggarIndependent Chairman of the Board
- MCMark C. SchneyerExecutive VP & CFO
- JJJennifer J. RhodesExecutive VP, Chief Legal Officer & Secretary
- TAThomas Andrew GarnerExecutive VP & Chief Commercial Officer
- SCScott CenciSenior VP, Chief Information & Data Officer
- LALaura A. BregeIndependent Director
- CACarol A. TammingaMember of the Scientific and Clinical Advisory Board
- HYHerbert Y. MeltzerMember of the Scientific and Clinical Advisory Board
- Company NameMirum Pharmaceuticals, Inc.Stock CodeMIRMPositionIndependent DirectorColleagues
- CPChristopher PeetzCEO & Director
- MGMichael G. GreyIndependent Non-Executive Chairman of the Board
- PRPeter RadovichCOO & President
- EHEric H. BjerkholtChief Financial Officer
- JGJean-Luc GirardetChief Technical Officer
- AMAndrew McKibbenSenior Vice President, Strategic Finance & Investor Relations
- LFLaurent FischerIndependent Director
- TPTimothy P. WalbertIndependent Director
